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Methods and Approaches for Assessing
Immunotoxicity: An Overview
by Jack H. Dean*, Michael 1. Luster* and Gary A.
Boorman*
The goals of the National Toxicology Program as they relate to immunological evaluation in
toxicity assessment are discussed. The advantages of immune function assays for defining
cellular injury as subtoxic levels following exposure to general or immunocyte specific chemical
toxicants are proposed. A comprehensive screening panel of immune function and host
resistance assays is presented in the context of an NIEHS approach for immunotoxicity
assessment and methods selection. A second panel for defining the mechanism underlying
immunological injury was also described. Studies utilizing these methods and approaches are
described in companion papers by our group.
Introduction
A major objective of the National Toxicology
Program (NTP) and a major effort at NIEHS is to
examine a variety ofin vivo and in vitro approaches
to assess toxicity as well as newer research
disciplines for evaluating chemicals of environmen-
tal concern. Immunology represents one of the
disciplines that the NTP is employing to examine
possible target organ toxicity as well as general-
ized toxicity at the cellular and molecular level.
Furthermore, the effects of chemicals on host
defense to bacterial, viral, fungal and parasitic
diseases as well as the surveillance and destruction
of neoplastically transformed cells are simulta-
neously being evaluated. It is our goal at NIEHS
to apply systematically the disciplines of immunol-
ogy and microbiology in a comprehensive manner
to study immunotoxicity and altered host resis-
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tance and to define a panel of sensitive assays to
screen for chemical-induced changes in immunolog-
ical and host resistance parameters. Extensive
studies conducted at NIEHS have suggested that
the route and time of exposure relative to the
maturational development of the immune system
should be ofparamount consideration in the design
of an evaluation protocol. Several studies have
demonstrated that pre- and postnatal exposure to
certain chemicals (e.g., TCDD or DES) during the
maturation of the thymus-dependent elements of
the immune system often produces more profound
immunological effects than adult exposure (1) or
produce long-lasting effects throughout adult life
(2). Thus, the focus ofthe discipline ofimmunology
on the evaluation of chemical toxicities may pro-
vide beneficialinformation to facilitate betterhuman
risk assessment.
Preliminary data indicate that examination of
immune function will add an extra level ofsensitiv-
ity and safety for defining toxicity at the cellular
level. The increased sensitivity of the immune
system for detecting cellular toxicity may result
from its rapid proliferation or the dynamic and
27highly regulated nature of its cellular components.
This concept is supported by human clinical che-
motherapy studies in which cells of the reticuloen-
dothelial system (RES) are among the most fre-
quent target cells for chemical injury. The functional
integrity of cell-mediated immunity (CMI) or the
quantitation of bone marrow progenitor elements
following chemotherapy is a popular means of
regulating drug dosage.
Comprehensive Panel for
Evaluating the Immunobiologic
Effects
A test for evaluating immunologic effects should
meet several criteria ifit is to be considered useful
and definitive. The test should result in data which
can be extrapolated to the human experience and
adaptable to practical considerations such as expense,
simplicity, time required for completion, reproduc-
ibility, uniformity and application to routine sub-
chronic or chronic toxicology studies. Certain com-
promises are associated with the development of
screening techniques. Ideally, immunologic assays
that will identify and assess the risk potential of a
chemical or drug are desirable; however, in general,
no single assay can accomplish this task, and as
such, a panel of selected assays that have been
validatedin experimental rodentmodels and human
clinical studies is recommended.
Currently, a wide variety of assays is being
utilized in the Immunology Program at the National
Institute of Environmental Health Sciences to
assess immunologic and host resistance alterations
following chemical exposure (Table 1). This is not
to suggest that it is necessary or even desirable
for evaluation laboratories to employ such a com-
prehensive assay panel. Rather, at our present
stage of knowledge, it is reasonable that a few
laboratories perform a comprehensive panel of
assays concurrently to determine the relative sim-
plicity, reproducibility and predictability of these
methods for detecting altered immunological and
host resistance functions. Some of these methods
will undoubtably be selected to screen new chemi-
cals and drugs for immunotoxicological potential.
The detailed methodologies of these assays as
performed at NIEHS have been described else-
where in detail (3). These procedures were selected
because they are reproducible and easily stan-
dardized. During the method selection phase of
our research, major emphasis has been placed on
assays that could be automated, routinized or
require only microquantitates of cells or body
fluids. These procedures involve the evaluation of
pathotoxicology indicators, host resistance models,
delayed-type hypersensitivity, cell-mediated immu-
Table 1. Comprehensive screening panel for defining immune alterations currently being evaluated at NIEHS.
Parameter
Pathotoxicology
Host resistance
Delayed hypersensitivity
Lymphocyte proliferation
Humoral immunity
Macrophage function
Bone marrow colony forming units
Procedure performed
Hematology profile (hemoglobin, red blood cell count, white blood cell count, differential)
Liver chemistries (SGPT, triglycerides, cholesterol)
Serum proteins (albumin, globulin, A/G, total proteins)
Weights (body, spleen, thymus, liver, kidney, heart, lung, brain)
Histology (liver, thymus, lung, kidney, spleen)
Tumor assays (tumor cell challengeTDio120 and radiometric tumor mass)
Listeria monocytogenes LDIo-20 challenge
Endotoxin hypersensitivity-LD1(-20
Expulsion of Trichinella spiralis
Radiometric assay with T-cell-dependent antigen
One-way mixed leukocyte culture
Mitogens (PHA, Con A, LPS)
Immunoglobulin levels (IgG, IgM, IgA)
Antibody response to T-dependent and T-independent antigens
Resident peritoneal cell numbers and nonspecific esterase staining
Phagocytosis of 51Cr-SRBC
Lysosomal enzymes (5'-nucleotidase, acid phosphatase, leucine amino peptidase)
Cytostasis of tumor target cells
Cytolysis of tumor target cells
RES clearance using 1 5I-trioleion
CFU-S (multipotent, hematopoietic stem cells)
CFU-GM (granulocyte/macrophage progenitor)
CFU-E (erythrocytes progenitor)
Cellularity
59Iron incorporation in bone marrow
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induced immune alterations.
Altered parameter Further procedures to perform
Pathotoxicology Bioaccumulation study
Hormone levels
Pair-feeding
Host resistance Virus challenge
Staphylococcus or Streptococcus
challenge (B-cell-dependent)
Cell-mediated immunity DHR using T-cell independent
antigen
Suppressor cell studies with
mitogens and cocultures
Helper cell studies
Spontaneous cytotoxicity
Lymphokine production
Antibody-mediated Mishell-Dutton assay and cocultures
immunity Local production of antibody
Titer of serum antibody-T-cell-
independent antigen
Bone marrow toxicity Serum levels of colony stimulating
factor (CSF)
CSF and prostaglandin synthesis by
macrophages and bone marrow
stromal cells
nity, humoral-mediated immunity, macrophage func-
tion and bone marrow progenitor cells. Attempts
are being made to correlate changes in immune
function with altered host resistance.
If the in vivo and in vitro data obtained from
such carefully planned studies using these screen-
ing procedures are negative, there can be reason-
able confidence in the safety of the drug or
chemical under the conditions and dosages defined.
A major limitation in risk assessment has involved
extrapolation of dose response curves from effect
to no-effect levels or from rodent model systems to
humans. However, if conservative extrapolations
are made by using data from appropriate assays,
the most relevant and accurate estimate possible
will be obtained. At present the methods listed are
in the validation and selection stage for later
application of some of these to routine toxicity
assessment when immunology studies are indicat-
ed.
If warranted by preliminary data, additional
tests can be used to examine the mechanisms by
which a particular chemical or drug alters immune
function (Table 2). These assays can provide addi-
tional information regarding mechanisms of im-
munotoxicity and may provide a means by which
to circumvent or abolish the undesired effects of
the agent. If the pathophysiologic mechanism
responsible for the effect or the target cell is
defined, possibly new analogs of the chemical or
drug can be synthesized which produce the desir-
able effects but not the undesirable ones (e.g.,
synthetic penicillin).
The following papers in this session describe, in
detail, methods and approaches utilized by leading
laboratories in this rapidly developing field.
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